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Abstract
The in vitro release characteristics of eight low-molecular-weight drugs (clindamycin, 17b-estradiol, 17b-estradiol-3-
acetate, 17b-estradiol diacetate, metronidazole, norethisterone, norethisterone acetate and oxybutynin) from silicone matrix-
type intravaginal rings of various drug loadings have been evaluated under sink conditions. Through modelling of the release
data using the Higuchi equation, and determination of the silicone solubility of the drugs, the apparent silicone elastomer
diffusion coefficients of the drugs have been calculated. Furthermore, in an attempt to develop a quantitative model for
predicting release rates of new drug substances from these vaginal ring devices, it has been observed that linear relationships
21 21
exist between the log of the silicone solubility of the drug (mg ml ) and the reciprocal of its melting point (K )
2 21( y5 3.558x2 9.620, R5 0.77), and also between the log of the diffusion coefficient (cm s ) and the molecular weight of
21the drug molecule (g mol ) ( y5 2 0.0068x2 4.0738, R5 0.95). Given that the silicone solubility and silicone diffusion
coefficient are the major parameters influencing the permeation of drugs through silicone elastomers, it is now possible to
predict through use of the appropriate mathematical equations both matrix-type and reservoir-type intravaginal ring release
rates simply from a knowledge of drug melting temperature and molecular weight.
  2003 Elsevier Science B.V. All rights reserved.
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Abbreviations: BKC, benzalkonium chloride; CLIN, clin-
damycin free base; E2, 17b-estradiol; E3A, 17b-estradiol-3-ace- 1 . Introduction
tate; EDA, 17b-estradiol-3,17-diacetate; IVR, intravaginal ring;
MET, metronidazole; NET, norethisterone; NETAc, norethis- Intravaginal rings (IVRs) are elastomeric drug
terone acetate; OXY, oxybutynin free base; A, drug loading per
23 23 delivery devices specifically designed to provide
unit volume (mg cm ); C , solubility in silicone oil (mg cm );SIL
2 21 controlled and sustained released of substances to theD , apparent silicone diffusion coefficient (cm s ); log K ,SIL o / w
log of the octanol–water partition coefficient; Q, cumulative vagina of the human female for either local or
22 21 21
release per unit area (mg cm ); R, gas constant (J K mol ); systemic effect (Fig. 1) [1–4]. Since the IVR con-
T , drug melting temperature (K); DH , drug lattice dissociationm d cept was first established in 1970 [5–7], most of the21
energy (J mol )
research has focused on the development of steroid-
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 steroids which permits relatively rapid molecular
diffusion. Specifically, drug release has been shown
to depend primarily on the silicone elastomer dif-
fusivity (D ) and the silicone elastomer solubilitySI L
(C ) of the drug molecule, as described by cumula-SIL
tive release Eqs. (1) and (2) for matrix and reservoir-
type devices, respectively [10,16,18–20]
]]]]]]Q5 D (2A2C )C t (1)œ SIL SIL SIL
D CSIL SIL
]]]Q5 ? t (2)hsheath
where Q is the cumulative amount of drug released
22per unit area of device (mg cm ), A is the drug
23loading (mg cm ), C is the solubility of the drugSIL
23in silicone elastomer (mg cm ), D is the dif-SIL
2 21fusivity of the drug in the elastomer (cm day ),
h is the thickness of the sheath layer (cm) and tsheath
is the time (days). However, the IVR platform might
also be effectively employed to deliver nonsteroidal
molecules, having the requisite physicochemical
characteristics, for a range of other therapies within
women’s healthcare. Yet, to date, the only nonsteroi-
dal drugs evaluated for IVR administration are
oxybutynin for the treatment of urinary incontinence
[21,22], nonoxynol-9 as a potential anti-HIV vaginal
microbicide [23], and bromocryptine mesylate for
the treatment of hyperprolactinaemia [24]. The pre-
conception still persists that silicone IVRs are only
suitable for the administration of steroidal molecules
for contraceptive and hormone replacementFig. 1. (A) Silicone intravaginal ring; (B) X-ray image showing
therapies.position of silicone intravaginal ring positioned in the human
female. Although a significant body of work has been
published to date on the development, application
three steroidal IVR products have now reached the and clinical testing of IVRs, no attempt has yet been

market: Estring (17b-estradiol; Pharmacia and Up- made to develop a model for predicting drug release
john), Menoring (17b-estradiol-3-acetate; Galen rates. In fact, only a small number of publications
Holdings), and Nuvaring (etonogestrel and ethinyl have been reported in the scientific literature which
estradiol; Organon). Much of the IVR literature focus on the major parameters influencing IVR
relates to crosslinked poly(dimethylsiloxane), or release rates, namely polymer solubility and dif-
silicone devices, although other elastomeric poly- fusivity [10,14,16,18,19,25]. Such a model would be
mers have been employed in recent years e.g. a particularly useful tool in evaluating the potential
poly(ethylene–co-vinyl acetate) and styrene– for new drug substances to be effectively released
butadiene block copolymers [15–17]. Silicone, in from a silicone IVR device. Necessarily, any predic-
particular, lends itself well to the release of steroid tive model should be based on real IVR release data,
molecules, a consequence of the relatively high and is likely to be based on certain physicochemical
solubility of steroids in the hydrophobic silicone and properties of the drug substances themselves. In
the relatively low molecular weight /volume of the order to elucidate the relative importance of these
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physicochemical parameters, the solid drugs of this (silica gel, eluent. ethyl acetate–hexane, 25:75)
study were selected to represent permeants having a yielded 16.04 g of estradiol-3,17-diacetate (94%
range of molecular size and hydrophilic / lipophilic yield, m.p. 120–121 8C). The chemical structure was
13 13
characteristics. In this study, the solubility and confirmed by C-NMR, FT-IR and HPLC. C-
diffusivity factors influencing the controlled release NMR: C=O signals, 169.38 and 170.36 ppm (cf.
of a range of steroidal and nonsteroidal molecules E3A, 169.40 ppm); FT-IR: C=O peaks, 1733.9 and
21from silicone IVRs have been determined, and a 1766.5 cm (cf. E3A, 1734.0 ppm).
model has been developed that will allow qualitative
assessment of the potential to release new drug 2 .3. High-performance liquid chromatographic
substances from silicone IVR devices.
analysis
HPLC assays were developed to quantify in vitro
2 . Materials and methods drug release from the IVRs (Section 2.5) and to
measure the solubility of the drugs in poly(di-
methylsiloxane) fluid (Section 2.6). Details of the2 .1. Materials
HPLC assays are summarized in Table 1 for each
drug. The HPLC instrumentation (Shimadzu, Kyoto,17b-Estradiol (E2) was obtained from Schering
Japan) consisted of a model SIL-10AXL autoin-Health (West Sussex, UK). 17b-Estradiol-3-acetate
jector, a model SCL-10A system controller, a model(E3A) was synthesized under GMP conditions by
LC-10AT solvent delivery module, a model FCV-Irotech (Cork, Ireland). Metronidazole (MET) was
10AL low-pressure gradient-flow valve, a model GT-supplied by Mediolast Spa (Milan, Italy). Norethis-
154 degassing unit, and a model SPD-10A UV–Visterone (NET) and norethisterone acetate (NETAc)
detector. Injection volumes were 10 ml.were supplied by Galen Holdings (Larne, Northern
Ireland, UK). Clindamycin (CLIN) was obtained
from Lek (Ljubljana, Slovenia). Oxybutynin free- 2 .4. Preparation of matrix-type intravaginal rings
base was supplied by Orgamol (Evionnaz, Switzer-
land). HPLC grade tetrahydrofuran, ethyl acetate and Matrix rings containing various drug loadings (50,
GPR grade hexane were purchased from LabScan 125, 250, 500 and 1000 mg) of CLIN, E2, E3A,(Dublin, Ireland). Benzalkonium chloride (BKC, EDA, MET, NET, NETAc and OXY were manufac-
50% aqueous solution), acetic anhydride and di- tured by reaction injection moulding according to the
methylpolysiloxane (viscosity, 20 cSt.) were pur- following standard method. A standard silicone
chased from Aldrich–Sigma (Poole, Dorset, UK). elastomer mix was prepared by mixing together 51.2
MED-6382 silicone elastomer base and tetrapropox- g tetrapropoxysilane and 2048.8 g MED 6382
ysilane crosslinker were supplied by Nusil Technolo- silicone elastomer base. The base consisted of a
gy (Carpinteria, CA, USA). Stannous octoate was mixture of high- and low-molecular-weight hydroxy-
obtained from Air Products and Chemicals (Penn- terminated silicones (M 5 10 000 and 2000, respec-n
sylvania, PA, USA). tively) and 25% (w/w) of the micronised reinforcing
filler diatomaceous earth. The required amount of
2 .2. Synthesis of estradiol-3,17-diacetate drug was added to and intimately mixed with 30.0 g
of the silicone mix. Stannous octoate (0.5%, w/w)
Freshly distilled acetic anhydride (4.95 g, 0.048 was then added, the elastomer mixture hand-mixed
mol) and anhydrous zinc chloride (0.03 g, 0.0002 for 30 s with a spatula and then injected via a
mol) were added to a solution of E3A (15.02 g, disposable 60-ml plastic syringe into the stainless
0.048 mol) in 120 ml of sodium-dried and distilled steel moulds of a laboratory-scale, electrically-heated
tetrahydrofuran. The solution was refluxed for 5 h IVR reaction injection moulding machine specifically
before removing the solvent to yield a crude white designed for the manufacture of intravaginal rings
powder. Purification by column chromatography (Technigal Division of Galen Holdings, Craigavon,
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T able 1
Details of HPLC assays for drugs
Drug Column Mobile phase Flow-rate Det.l Retention
(ml /min) (nm) (min)
CLIN Hypersil ODS BDS CH CN–0.02 M buffer, 1.0 210 5.293
4.63150 mm, 5 mm pH 5–water (25:44:31)
E2 Sphereclone ODS2 CH CN–H O (50:50) 1.5 220 2.363 2
4.63150 mm, 5 mm
E3A Hypersil ODS BDS CH CN–H O (50:50) 1.5 220 5.843 2
4.63150 mm, 5 mm
EDA Sphereclone ODS2 CH CN–H O (90:10) 1.0 220 2.963 2
4.63150 mm, 5 mm
MET Hypersil ODS BDS CH CN–0.02 M buffer, 1.0 277 2.133
4.63150 mm, 5 mm pH 5.0 (20:80)
NET Sphereclone ODS2 CH CN–H O (50:50) 1.5 220 2.783 2
4.63150 mm, 5 mm
NETA Sphereclone ODS2 CH CN–H O (50:50) 1.5 220 5.053 2
4.63150 mm, 5 mm
OXY Luna ODS CH CN–0.02 M buffer, 1.5 220 2.003
4.63150 mm, 5 mm pH 5.0 (45:55)
UK). The injection mixes were cured at 80 8C for 2 2 .6. Determination of drug solubility in silicone oil
min producing elastomeric silicone rings weighing
10.260.1 g and having the following dimensions: Approximately 100 mg of each drug was added to
7.5 mm cross-sectional diameter, 43.0 mm internal 3.0 ml of 20 cSt poly(dimethylsiloxane) fluid. After
diameter, 58.0 mm external diameter. The surface equilibration for 72 h in a shaking orbital incubator
2
area (using equation s5 4 p bc where s is surface at 37 8C, the saturated silicone solutions were filtered
area, b is the cross-sectional radius and c is the at 37 8C (Nalgene cellulose acetate filters, 0.2 mm)
2 2
external radius) and volumes (using v5 2p b c) of and 1.0 ml of the silicone filtrate was then extracted
3the IVRs were calculated to be 37.4 and 7.01 cm , with 50 ml of the relevant mobile phase (Table 1).
respectively. Drug solubilities in silicone (C ) were then de-SIL
termined using the HPLC assays already described
for each drug substance (Section 2.3).
2 .5. Drug release studies
The steroid-containing rings were individually 3 . Results and discussion
placed in stoppered 250-ml conical flasks containing
100 ml of a 1% (w/w) aqueous BKC solution. For The solid, micronised, pharmaceutical grade drugs
CLIN, MET and OXY release experiments, 100 ml employed in this study were incorporated into the
of 0.02 M phosphate buffer, pH 5.0, was employed. silicone elastomer base at various loadings and cured
The release mediums were selected to maintain sink at an elevated temperature produce IVRs containing
conditions over a 24-h release period. The flasks a homogeneous dispersion of the drug within the
were shaken for 14 days in an orbital incubator matrix environment of the crosslinked silicone elas-
(Sanyo Gallenkamp Model IOX400.XX2.C, 60 rpm, tomer. The rings thus displayed typical matrix-type,
37 8C, 32 mm orbit diameter) with samples taken and diffusion-controlled release characteristics where
release medium replaced fully every 24 h. Release mean daily drug release was proportional to drug
studies were performed in triplicate. concentration, as exemplified in Fig. 2 for norethis-
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Fig. 3. Cumulative release per unit area (Q) versus root time
Fig. 2. Fourteen-day daily release profiles of norethisterone from profile for norethisterone matrix-type intravaginal rings of various
matrix-type intravaginal rings of various drug loadings. j, 50 mg; drug loadings. j 50 mg; , 125 mg; m, 250 mg; d, 500 mg; *,
, 125 mg; m, 250 mg; d, 500 mg; *, 1000 mg. 1000 mg.
of the drugs investigated. The trend in increasingterone-loaded IVRs. Similar matrix-type release pro-
release rates was CLIN,E2,NET,MET,E3A,files were obtained for the other drug-loaded IVRs.
NETAc,EDA,OXY. Entirely similar trends wereThe release profiles are characterized by an initial
observed for the other drug loadings.burst followed by a gently decreasing daily release.
Acetylating the 3-hydroxyl and 17-hydroxylThe standard deviation for each mean daily release
groups of E2 and NET, respectively, provided sig-data point (n53) is smaller than the height of the
nificantly faster release rates than the correspondingplot symbols (coefficient of variance ,2%) and error
1 / 2parent steroid. For E3A, the Q /t flux rate wasbars have therefore been omitted. This high degree
some 7 times greater that for E2, while NETAcof reproducibility in in vitro studies is typical for
provided a 4.5-fold enhancement over NET. AIVRs produced in our laboratory, which are manu-
further increase in the flux rate is observed for EDA.factured by reaction injection moulding on a labora-
The trend in release amongst the structurally-similartory-scale ring making machine using precision-en-
steroids seems to relate to the number of hydroxylgineered stainless steel moulds identical to those
groups within the steroids-E2, NET, E3A, NETAcused in the commercial manufacturing process.
and EDA have 2, 1, 1, 0 and 0 hydroxyl groups,According to the Higuchi equation [Eq. (1)],
diffusion-controlled release from matrix-type IVRs
1 / 2
should produce linear Q versus t cumulative T able 2
release profiles having a gradient equal to Flux rates of drugs from 250- and 1000-mg loaded matrix-type
0.5[D C (2A2C )] , as exemplified for intravaginal ringsSIL SIL SIL
1 / 2 22 2 / 2norethisterone IVRs in Fig. 3. IVRs loaded with the Drug Q /t (mg cm t )
other drug substances displayed entirely similar
250 mg IVR 1000 mg IVR2profiles. The linear correlation coefficient, r , for the
1 / 2 CLIN 0.063 0.13814-day Q /t profiles was .0.995 for each IVR
E2 0.120 0.269formulation except the 50 mg NETAc and 50 mg E3A 0.847 1.778
EDA rings where drug exhaustion of the matrix was EDA 1.117 2.3262
evident beyond day 10. However, r .0.997 over 10 MET 0.278 0.658
NET 0.252 0.535day release profiles for these rings. The cumulative
1 / 2 NETAc 1.139 2.255release flux rates (Q /t ) for the 250- and 1000-mg
OXY 3.069 6.893drug-loaded rings are presented in Table 2 for each
222 K. Malcolm et al. / Journal of Controlled Release 90 (2003) 217–225
 polar molecule in the hydrophobic silicone elas-
tomer.
2Values of Q /t, obtained by squaring the line
1 / 2gradients from the Q versus t plots (Fig. 3), were
then plotted against (2A2C ), producing aSIL
straight-line correlation of gradient D C accord-SIL SIL
2ing to Eq. (1). The linear Q /t versus (2A2C )SIL
plot for the NET rings is presented in Fig. 4. Matrix
IVRs containing the other drug substances produced
2
similar straight-line Q /t versus (2A2C ) plotsSIL
2(r .0.993), the gradient product D C of whichSIL SIL
are presented in Table 3. The trend in increasing
magnitude of the D C values (CLIN,E2,SIL SIL
NET,MET,E3A,NETAc,EDA,OXY) reflects
2 the trend observed for increasing release flux ratesFig. 4. Linear relationship between Q /t and (2A2C ) forSIL 1 / 2Q /t (Table 2).norethisterone matrix-type intravaginal rings, with line gradient
equal to D C , according to the Higuchi equation. Having arrived at an experimentally derived valueSIL SIL
for the product of the diffusion coefficient and the
solubility of the drug in silicone elastomer, a value
respectively. Based on the previous discussion de- for the diffusion coefficient may be easily calculated
scribing the parameters influencing release of drugs if the solubility of the drug in silicone can be
from silicone systems, the increases in drug release measured. Several methods for determining the
rate as a result of mono- or diacetylation can be silicone solubility of compounds have been reported
attributed to an increase in the drug solubility in the in the literature, including (i) the use of a low-
silicone elastomer (C ) and/or an increase in the molecular-weight / low-viscosity silicone oil as aSIL
silicone elastomer diffusion coefficient (D ). It is surrogate for silicone elastomer [10,18,19,26,27], (ii)SIL
likely that the former proposition is correct since the differential scanning calorimetry [28], (iii) dynamic
rate of molecular diffusion, and thus release, is mechanical analysis [19], and (iv) diffusion of drug
expected to be slower for the larger acetylated from a saturated drug solution into a thin film of
derivatives. silicone elastomer [16]. The silicone oil method was
It is also interesting to note that the relatively adopted in this study owing to its simplicity. The
small molecular weight / size of MET did not trans- solubility of each drug in silicone oil at 37 8C (C )SIL
late into the fastest release rate, suggesting that its is presented in Table 3. The trend in increasing
release rate from the silicone IVR might be largely solubility is E2.MET.CLIN.NET.E3A.
determined by the limited solubility of this relatively NETAc.EDA.OXY. It is apparent that the differ-
T able 3
Physicochemical, intravaginal ring release, silicone diffusion and silicone solubility characteristics of drugs
Drug Melting mw D C C (37 8C) D log DSIL SIL SIL SIL SIL
21 21 21 23 2 21 2 21
substance point (8C) (g mol ) (mg cm day ) (mg cm ) (cm s ) (cm s )
28CLIN 142 425 0.00008 0.009 1.03310 26.99
26E2 175 272 0.00038 0.004 1.10310 25.96
27E3A 137 314 0.01715 0.237 8.38310 26.08
27EDA 125 356 0.02976 1.310 2.63310 26.58
26MET 159 171 0.00246 0.006 4.75310 25.32
26NET 203 298 0.00151 0.015 1.17310 25.93
27NETAc 161 340 0.02829 0.655 5.00310 26.30
27OXY 57 357 0.21764 11.249 2.24310 26.65
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 ences observed in the IVR release characteristics of
the various steroids (Table 2) are largely attributed
to the differing silicone solubilities of these com-
pounds. Clearly, acetylation of the hydroxyl groups
of E2 and NET enhances silicone elastomer solu-
bility. The relatively polar metronidazole and clin-
damycin (log K 0.0 and 2.0, respectively, com-o / w
pared with higher values of 3.9, 4.0, 5.0, 3.0, 4.0 and
4.0 for E2, E3A, EDA, NET, NETAc and OXY,
respectively [29–31]) and the presence of two free
hydroxyl groups in E2 contribute to their limited
solubility in the hydrophobic silicone. Interestingly,
the results suggest that acetylating metronidazole at
its free hydroxyl group may produce a pro-drug with
significantly enhanced silicone solubility and hence
Fig. 5. Linear relationship between the logarithm of the siliconeincreased release rate compared to metronidazole
solubility and the reciprocal of the drug melting temperature.itself, a pro-drug approach that has already been
successfully adopted in the development of Galen
Holdings’ estradiol-3-acetate IVR [10,18].
The dramatic differences observed in the silicone surface for temporary Langmuir adsorption and
creating a more tortuous diffusion pathway [33–35].solubilities of the drug molecules can be attributed to
28the variations in chemical structure / functionality. The diffusion coefficient values range from 1310
26 2 21According to the theory described earlier, the disso- to 5310 cm s and are similar to those reported
lution of a drug crystal in a polymer composition can for other diffusants in silicone elastomer systems
be considered to consist of a dissociation step [36–39]. The diffusion process can be considered as
followed by a dissolution step. The former requires a a ‘jumping’ mechanism wherein a solubilised penet-
dissociation energy and is dependent upon the melt- rant molecule spends long periods of time (up to 1
ing temperature of the drug, according to Eq. (3) ns) located within a pocket of free volume (a void)
[20,32] within the polymer structure before a temporary
channel opens up with a neighbouring pocket. If theDHd
]]]log C 5 constant1 (3) penetrant has a suitable velocity it may jump be-p 2.303RTm tween the two pockets of free volume via the
where C is the mole fraction solubility of the drug, channel. The channel then closes and the permeant isp
DH is the drug lattice dissociation energy, R is the entrapped within a different void. It is the rate andd
gas constant, and T is the drug melting temperature. distance of this jumping motion that governs the ratem
The exponential relationship between the silicone of diffusion [40,41]. Intuitively, the molecular size /
solubility and the reciprocal of the melting point for volume of the diffusant is likely to be an important
the drugs of this study is demonstrated in Fig. 5. factor in this diffusional process. Accordingly, a
From the values of D C and C (Table 3), linear relationship (R50.952) between the log of theSIL SIL SIL
the apparent silicone diffusion coefficients (D ) of apparent silicone diffusion coefficient (Table 3) andSIL
the drugs in silicone have been calculated (Table 3). the relative molecular weight for each drug substance
The silicone diffusion coefficient is described as was observed (Fig. 6). Importantly, the graph allows
‘apparent’ in recognition of the fact that the diffu- the diffusion coefficient of any drug in MED-6382
sional process does not take place though a pure silicone elastomer to be predicted with a reasonable
silicone polymer; the silicone elastomer base used to degree of accuracy based solely on a knowledge of
manufacture the IVRs includes a diatomaceous earth its molecular weight. (Of course, the diffusion
reinforcing filler which is known to influence the rate coefficient will vary for other silicone elastomer
of diffusion of the permeating species by providing a formulations, which may have different degrees of
224 K. Malcolm et al. / Journal of Controlled Release 90 (2003) 217–225
 developed that will allow the prediction of daily flux
rates for any new drug substance based solely on a
knowledge of the molecular weight and melting
temperature of the drug. Specifically, linear relation-
ships were observed between the experimentally
determined silicone diffusion coefficient and the drug
molecular weight, and between the log of the ex-
perimentally determined silicone solubility and re-
ciprocal melting temperature of the drug. The results
will enable researchers to evaluate the potential of
releasing new drug entities at therapeutic amounts
from core and matrix type IVR devices.
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